Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

PBL to Develop an Affinity Ligand for Purification of Novartis Vaccine

  • ProMetic Biosciences (PBL) will develop a synthetic ligand affinity adsorbent for the purification of Novartis’ new vaccine product currently in clinical trials.

    Under the terms of the agreement Novartis will fund PBL to screen its Chemical Combinatorial Libraries® for ligands suitable for the processs-cale purification of its recombinant protein vaccine. The work will be conducted at PBL's research laboratories in Cambridge Science Park, U.K.

    PBL states that owing to their high selectivity, robustness, and low cost compared to ligands derived from biological sources, Mimetic Ligands™ provide biopharmaceutical manufacturing companies with numerous advantages, particularly for large-scale production of price-sensitive products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »